asymptotically stable equilibria, one of which corresponds to the AIDS status while the other corresponds to LTNP status. Unfortunately, with few exceptions, the parameters of the human body are such that the state of an HIV-positive patient is located in the region of attraction of the equilibrium corresponding to the AIDS status, rather than LTNP status. Accordingly, patients without medication normally progress to AIDS. It is obviously desirable that the state of the patient be driven into the LTNP region of attraction, where the patient does not progress to AIDS and drug treatment can be stopped.
This article focuses on the scheduling of drug therapy to drive the patient to LTNP status. To address this problem, structured treatment interruption (STI) [8] , [11] , [12] switches between zero and maximal medication. However, STI scheduling depends on the values of the model parameters and thus is vulnerable to parametric uncertainty. Also, the results of [8] , [11] , and [12] indicate the possibility of attaining LTNP status but do not provide systematic drug-scheduling methods for driving the patient to LTNP status.
In [13] and [14] , model predictive control (MPC) tools are applied to the model of [11] to determine when a full dose or no medication is allowed. However, this feedback control method relies on the accurate and timely measurement of all of the model states and thus is unrealistic. A variation of the scheme used in [13] and [14] , as well as the effect of using a continuous function of drug efficiency, is considered in [15] . In [16] , a control strategy based on gradual dose reduction induces cytotoxic T lymphocyte (CTL) mediated control and yields LTNP status.
This article describes a drug scheduling method based on a reduced-order model, which does not require estimates of all of the parameters and states of the full-order model. To this end, we divide the full-order model into two subsystems, one of which is modified to approximate the full-order model. We show that the suggested method drives the HIV patient state into the LTNP region of attraction.
This article is organized as follows. First, the problem under consideration is formulated, and a description of the HIV infection model is provided. Then, measurement methods for the states of the HIV model are surveyed. Subsequently the HIV infection model is modified to yield a reduced-order model. Finally, two control strategies based on this modified model are presented along with simulation results. The article concludes with a discussion and ideas for future work.
PROBLEM FORMULATION
Several mathematical models describing the interactions between the HIV and the immunocytes in the human body are available [1] , [17] . We consider the HIV infection model of [11] , which includes LTNP equilibrium. This model is given by 
where the states x, y, z 1 , w, and z 2 describe the populations of specific cells in a unit volume of blood and therefore are meaningful only when nonnegative. As indicated in Table 1 , x is the concentration of uninfected CD4 T-cells, y is the concentration of infected CD4 T-cells, z 1 is the concentration of helper-independent CTL, w is the concentration of CTL precursors, and z 2 is the concentration of helper-dependent CTLs.
The population of healthy (uninfected) CD4 T-cells increases at a rate λ (since the cells are produced by the thymus) and decreases in the absence of HIV at a rate dx (since the cells die naturally), which is proportional to the population of x. Uninfected CD4 T-cells are infected at a rate that is proportional to the product of x and y because the CD4 T-cell x is a target of HIV and the infected CD4 T-cells y produce new virus. The infected cell y dies out at a rate ay. In addition, the model describes the adaptive cellmediated immune system. This system consists of the precursor CTL w, which provides long-term memory for a specific antigen, HIV in this case, as well as the effector CTL z 2 , which has the role of destroying the infected cell y at the rate p 2 z 2 y. The cell w differentiates into the cell z 2 at the rate c 2 qy w. In other words, the model implies that large populations of the infected cells y and of the precursor CTL w make the population of z 2 increase more rapidly. The term c 2 xy w in (4) implies that the precursor CTL w is generated at a rate proportional to the concentrations of x, y, and w. The helper-independent component of the CTL response is represented in this model by z 1 . These cells proliferate without CD4 T-cell help at the rate c 1 z 1 y, and destroy infected cells at the rate p 1 z 1 y.
The quantity η, which varies between 0 and 1, describes the effect of the drug. In the presence of a control input, η can be rewritten as where η * is the maximal effect of the drug. For example, η * = 0.98 indicates that the maximal effect of the drug is 98%. From a control perspective, the input u, which has values between zero and one, represents the drug dose of highly active antiretroviral therapy (HAART). If u = 1, a patient receives the maximal HAART therapy, while u = 0 means no medication. However, u is restricted to be either zero or one because the use of partially suppressive therapy, that is, 0 < u < 1, is difficult to achieve in practice [14] . In addition, drug therapy at less than full dosage must not be applied because of the higher probability of the emergence of drugresistant strains of HIV [14] . Consequently, (1) becomeṡ 2 , and h are positive constants. The population of HIV is not explicitly modeled because it is approximated by y.
When a patient is treated, it is desired that the drug be eventually terminated. To investigate this possibility, we determine the five equilibria of the full-order model (1)-(5) as in Table 2 [18] . The stability properties of these equilibria are evaluated with the parameter set of [11] , [13] , and [14] given in Table 3 . Under the assumption that η = 1, which corresponds to the case of no medication, the interpretation of each equilibrium is as follows. Equilibrium A indicates the status of a person who does not have HIV. With the parameters of Table 3 , this equilibrium is unstable, which explains why it is difficult to revert a patient, once infected, back to the HIV-free status when the medication is stopped. Equilibria C and E are locally exponentially stable. Equilibrium C is the status of a patient for whom HIV dominates. Equilibrium E is for a HIV-positive patient who does not progress to AIDS. For this reason, 
.
this status is referred to as LTNP. With the parameters of Table 3 , the number y (E) of infected cells is low, while the number w (E) of CTL precursors is large, which is desired. The control goal is to drive the state near this equilibrium from any initial state. Note that the HIV patient state cannot be induced to LTNP status if full dose of HAART medication is applied every day [8] , [11] , [13] [14] [15] [16] , [18] . Equilibria B and D, which are unstable for the parameters of Table 3 
Theorem 1
For every input function η(·) ∈ U , finite-time escape cannot occur, and the set P is positively invariant. In other words, for every η(·) ∈ U and initial condition X(0) ∈ P , the solution X(t) of (1)- (5) exists for all t ≥ 0, and is contained in P for all t ≥ 0.
Proof
Let X(0) ∈ P , and assume that some component of X(t) escapes at the finite time T > 0. Since (2), (3), and (4) have the linear form
, where f y (t), f z 1 (t), and f w (t) are continuous on [0, T), the states y(t), z 1 (t), and w(t) remain positive for 0 ≤ t < T. During this time interval, the states x(t) and z 2 (t) also remain positive since y(t) and w(t) are continuous and positive, ẋ > 0, and ż 2 > 0 by (1) and (5) for x = 0 and z 2 = 0, respectively. Hence
where k = min{d, a}. Thus V(t) (and hence, x(t) and y(t)) is bounded on the interval 0 ≤ t < T . Indeed, for 0 ≤ t < T , the functions f z 1 (t) = c 1 y(t) − b 1 and f w (t) = c 2 x(t)y(t) − c 2 qy(t) − b 2 are bounded. Therefore, z 1 (t) and w(t) do not diverge to infinity by the boundedness of f z 1 (t) and f w (t) in (3) and (4) . Then, due to (5), z 2 (t) is also bounded. Hence finite escape does not occur and P is positively invariant.
HIV MEASUREMENTS
To analyze and treat an HIV-infected patient, measurements of HIV dynamics are needed. In this section we summarize the status of measurements related to HIV infection dynamics. Several types of antibody tests, such as enzyme-linked immunosorbent assay (ELISA) and western blot, are not discussed because these tests cannot give quantitative data on the amount of the antibody. For additional information about HIV antibody testing, see [19] .
Viral Load Tests
Viral load tests, which return the corresponding levels of the y state, are also known as viral load assays, polymerase chain reaction (PCR) tests, or branched deoxyribonucleic acid (bDNA) tests [20] . These tests work by looking for HIV genetic material, the ribonucleic acid (RNA). Each test has a threshold viral level, below which it cannot reliably detect HIV genetic material. This limit for clinical technology is currently 50 copies/ml [21] , although some advanced experiments can detect HIV down to 5 copies/ml [22] . Each test is highly reliable and repeatable and thus is used with a CD4 T-cell count to monitor the progress of an HIVinfected patient.
Flow Cytometry and CD4 T-Cell Count
Examination of lymphocyte populations is possible because their cell surface markers are uniquely expressed. Monoclonal antibodies are used to identify T lymphocytes in human blood [23] . These antibodies are labeled with fluorescent markers [24] . A flow cytometer is designed to automate the analysis and separation of cells stained with fluorescent antibodies. The flow cytometer uses a laser beam and a light detector to count single intact cells in suspension (see Figure 1 ). Every time a cell with a fluorescent antibody passes the laser beam, the cell is excited by the laser and emits light, which is deflected and recorded by a detector. This instrument can sort populations of cells into various containers according to their fluorescence.
In HIV treatment, the measurement of T-cell subpopulations, such as a subpopulation x of CD4 T-cells, a key indicator of the prognosis of AIDS, is routinely performed by flow cytometric analysis. Although trained users of a flow cytometer can obtain accurate results quickly and easily, this measurement method has limitations because measuring specific cells requires the corresponding fluorescent antibody to stain the target cells. For example, to TABLE 3 Parameters and initial conditions. All simulations use these typical system parameters, which are given in [11] , [13] , [14] . measure unusual cells, the required antibody may be costly or difficult to obtain [25] .
MODIFICATION OF THE MODEL
We first consider the full-order model (1)- (5) as the interconnection of two subsystems, namely, the infection dynamics and the immune system. The infection dynamics are modeled by means of the two-dimensional nonlinear systemẋ
whose inputs are u and p 1 z 1 + p 2 z 2 , and whose outputs are x and y. Next, the immune system is modeled by the threedimensional nonlinear systeṁ
whose inputs are x and y, and whose output is
The interconnection of these subsystems is shown in Figure 2 .
We consider the full-order model (1)- (5) as the interconnection of two nonlinear systems for several reasons. First, it is currently not possible to measure all of the states of the full-order model (1)- (5) with high accuracy [14] . In particular, as discussed in the previous section, we can assume that only the CD4 T-cells x and the HIV loads y are measured accurately. Therefore, the system (7), (8) includes the states that can be measured reliably, whereas the system (9)- (11) has unmeasured states.
Second, it might be impossible to estimate the parameters of the immune system due to the lack of measurements of the immune system states. Even if estimation were possible, it may be impractical to estimate these parameters for each HIV patient. Therefore, by decomposing the full-order model (1)- (5) into two parts and dealing only with one part, we avoid the need to estimate the immune system parameters. For additional information about parameter estimation in HIV dynamic models, see [26] and [27] .
Third, although the full-order model (1)-(5) describes the human immune system with both helperdependent CTL and helper-independent CTL, the immune system is only approximately modeled by a low-order system of differential equations. Therefore, we separate the well-modeled part (7), (8) from the poorly modeled part (9)- (11) . Note that the model used in [28] has an alternative immune system, which is different from (9)- (11) . In the infection dynamics (7), (8), we can regard the effect on the virus load from the immune system (9)- (11) as the positive function
The system (7), (8) consists of the model used in [1] as well as φ, which corresponds to the control effect of the virus load produced by the system (9)- (11) . By appending φ, the virus dynamic model of [1] becomes the system (7), (8) .
For these reasons, we seek a control method that depends only on (7), (8) . To realize such a method, we note that (8) includes the states z 1 and z 2 , while (7) has only the states x and y. Our goal is thus to modify (8) so that the modified system exhibits dynamic behavior similar to that of the full-order model (1)- (5) 
FIGURE 2
Connection between the infection dynamics and the immune system. We consider the full-order model (1)- (5) We know that the full-order model (1)- (5) has two positive asymptotically stable equilibria with the typical parameter set. Therefore, when u = 0, the modified infection dynamics must have analogous equilibria for these parameters. Thus, as a candidate for the modified infection dynamics, we consider the reduced-order model
where A, B, C, and D are real numbers with D nonzero. When u = 0, (12), (13) becomeṡ
The equilibria of (15) are determined by solving
To be consistent with the full-order model (1)- (5), (16) must have three real solutions, namely, K 1 , K 2 , and K 3 , where
Then A, B, and C are such that (14), (15) . If the initial value of y is between 0 and K 2 , then y(t) tends to K 1 . Then x(t) tends to λ/(d + β K 1 ) according to (14) . If an initial state has a value of y greater than K 2 , then y(t) tends to K 3 , and x(t) tends to λ/(d + β K 3 ). Therefore, the two-dimensional region of attraction for the equilibrium [(λ/d + β K 1 ), K 1 ] is 0 < y < K 2 , while the two-dimensional region of attraction for the equilibrium
With the typical parameter set and u = 0, the full-order model (1)- (5) D and K 2 remain undetermined. At this point, we know only that K 1 < K 2 < K 3 , D < 0, and |D| must be sufficiently small. If |D| is large and u = 1, then, with the typical parameters, the dynamics of (12), (13) do not vary dramatically, whereas those of the full-order model (1)- (5) do. In the next section it is assumed that D and K 2 are fixed, and the first control methodology is presented.
CONTROL STRATEGY WITH CONSTANT PARAMETERS
In this section, we assume that D and K 2 are constant and suggest a control strategy with constant parameters (CSCP). With this assumption, all of the parameters of (12), (13) are determined. The basic concept of the control strategy is that a low-order system (12), (13) for the modified infection dynamics is used as an emulator of a high-order system, the HIV patient.
The idea of using the reduced-order model (12), (13) in HIV treatment is as follows. We assume that the patient has HIV measurement tests at the beginning of a period of length T. Within the period T, the reduced-order model (12), (13) can exhibit dynamic behavior similar to that of the high-order system. From HIV measurements, the CD4 T-cell count and viral load can be thought of as the values of the states x and y, respectively. Therefore, we set these levels as the initial values of (12), (13) at the beginning of the period. During the period, we consider (12), (13) as an emulator of the patient. Then we estimate the CD4 T-cell count and viral load of the patient by referring to the states x and y of (12), (13), respectively. The HIV measurements of the patient are available only once in each period, whereas the states x and y of the reduced-order model (12), (13) are available as desired by means of numerical integration.
Using (12), (13) we decide whether the anti-HIV therapy is taken on each day. In other words, the states x and y of the reduced-order model (12), (13) are available at the beginning of each day by means of numerical integration. This decision depends only on the value of y, because y = K 2 is the boundary of the LTNP region of attraction in the reduced-order model (12), (13) . If the state y of the reduced-order model (12) , (13) is lower than K 2 at the beginning of the day, the anti-HIV medication is not administered to the patient for the day. Otherwise, the medication is administered to the patient.
Control Steps of CSCP
The idea of CSCP is realized by the following steps. Note that times are in days.
Initialization
Three positive numbers T, N, and K 2 ; a negative number D; and a function u D (t) (0 ≤ t ≤ 1 day) of daily drug effect are chosen. T denotes the time period between each set of HIV measurements, while N denotes the total number of HIV measurements during medication. Therefore, the period of total medication is NT days. Let n T denote the number of days after the last HIV measurement, and let n N denote the number of HIV measurements after the beginning of the medication. Therefore, with the initialization n T = 0 and n N = 0, a generic day of the treatment can be denoted as the (n N T + n T )th day.
» Step 1) The present CD4 T-cell count and viral load are measured, and we set x M (n N T) and y M (n N T) from these measurements. The subscript M indicates that the values are obtained from measurements. Set
The subscript I indicates the initial value for the reducedorder model (12), (13) for each day. » Step 2) At the beginning of each day, if y I (n N T + n T ) ≥ K 2 , then full drug therapy is applied to the HIV patient, and we set the input u(n N T + n T + t) = u D (t) (0 ≤ t ≤ 1 day) in the reduced-order model (12), (13) . Otherwise, no medication is applied, and we set the input u(n N T + n T + t) = 0 (0 ≤ t ≤ 1 day) in the reducedorder model (12), (13) . » Step 3) Integrate the reducedorder model (12), (13) for one day with the initial point
and y F = y(n N T + n T + 1), where the subscript F indicates the final value of the reduced-order model (12), (13) . » Step 4) If n T = T, then go to Step 5. Otherwise, increase n T by one, set x I (n N T + n T ) = x F , y I (n N T + n T ) = y F , and go to
Step 2. » Step 5) If n N = N, then terminate this routine. Otherwise, set n T = 0, increase n N by one, and go to Step 1. A flow chart illustrating these control steps is given in Figure 3 .
Simulations of CSCP
In this subsection, two computer simulations of CSCP are presented. We regard the full-order model (1)- (5) as the HIV patient in the simulations. All simulations use the typical system parameters of [11] , [13] , and [14] and one of the initial conditions of [13] and [14] , as indicated in Table 3 . Note that the initial point is in the vicinity of equilibrium C when u = 0, which corresponds to a seriously progressed HIV infection. The design variables are defined as
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FIGURE 3
Control strategy with constant parameters D and K 2 . T denotes the time period between each set of HIV measurements, while N denotes the total number of HIV measurements during the course of medication. Therefore, the total medication period is NT days. n T is the number of days since the last HIV measurement, and n N is the number of HIV measurements after the beginning of the medication. Therefore, a generic day of the treatment is denoted as the (n N T + n T )th day. Integrate model (12) , (13) for one day with (x I (n N T + n T ), y I (n N T + n T )) and u (n N T + n T + t). From the solution, set x F = x(n N T + n T + 1) and y F = y(n N T + n T +1).
No medication is applied to the real system. u (n N T + n T + t) = 0, (0 ≤ t ≤ 1).
Full drug therapy is applied to the real system. u (n N T + n T + t) = u D (t), (0 ≤ t ≤ 1). n T = n T + I, x I (n N T + n T ) = x F, y I (n N T + n T ) = y F. n N = = N K 1 = 0.0216, K 2 = 1.5451, K 3 = 3.3333, D = −0.6, N = 600, T = 4 for the first simulation, and T = 7 for the second simulation. K 1 and K 3 are determined as discussed in the previous section.
Yes
The value K 2 = 1.5451 is selected according to Table  2 as the only equilibrium value of y such that
We assume that the daily drug treatment implies a square-wave profile of u during the day because HAART drugs are usually taken orally at fixed doses and the drug absorption dynamics cannot be manipulated arbitrarily. In particular, the function of the one-day drug effect u D (t) (0 ≤ t ≤ 1 day) is assumed to be given by
Discussion
In the first simulation of this strategy (Figure 4 ), the drug therapy is terminated around the 200th day. After the termination of the therapy, x(t) and w(t) increase slowly, and y(t) decreases slowly in the full-order model (1)- (5). The state in the full-order model (1)- (5) is successfully driven to LTNP status because T is sufficiently small that the reduced-order model (12), (13) emulates the behavior of the full-order model (1)- (5), although the reduced-order model (12), (13) uses constant values of D and K 2 . However, in the second simulation of the strategy ( Figure  5 ), the drug treatment does not end within the length of the simulation. The strategy fails to bring the HIV patient to LTNP status because T is too large for (12), (13) to emulate (1)- (5) effectively with fixed D and K 2 . The next section presents a revised control scheme. Figure 5 shows a recurring pattern before the end of the simulation. This pattern implies that CSCP fails to drive the state into the LTNP region of attraction. To break this pattern, we modify the values of D and K 2 during the medication and suggest a control strategy with time-varying parameters (CSVP). If we adjust D and K 2 once every period T, this pattern can be prevented. In this section, a method for adjusting D and K 2 is described and illustrated. At the beginning of a new period, let t = n N T. From the previous period we know the initial point (13), the final point (x F , y F ) of the reduced-order model (12), (13) , the values of D and K 2 , and the history of the input u(t), where n N T − T ≤ t ≤ n N T. Also, we can find the current levels of the CD4 T-cell count and viral load (x M (n N T), y M (n N T) ) from measurements on the HIV patient. Although particular values of D and K 2 are used for the previous period, there may exist alternative values of D and K 2 that reduce the error between the reduced-order model (12), (13) and the patient if applied instead. We define the difference ε = y F − y M (n N T) between y F and y M (n N T) as the error between the reduced-order model (12), (13) and the patient. Figure 6 shows a conceptual representation of the initial point of the reduced-order model (12), (13) for the previous period, the final point of the reduced-order model (12), (13) 
CONTROL STRATEGY WITH TIME-VARYING PARAMETERS
(x M (n N T − T), y M (n N T − T)) of the reduced-order model (12),
FIGURE 4
Simulation result of the control strategy with constant parameters D and K 2 and with T = 4. These plots show the control input u(t) and state histories for the full-order model (1)- (5) and the reduced-order model (12) , (13) . The drug therapy is terminated around the 200th day. After the termination of the therapy, the state in the full-order model (1)- (5) is successfully driven to long-term nonprogressor status. Model (1)- (5) w (t ) in Model (1)- (5) y(t) in Model (12), (13) 
Model (12), (13) K 2 and solve an optimization problem to minimize ε 2 within the rectangular region. 
Control Steps of CSVP
where y * (n N T) is the y component of the solution of the reduced-order model (12) , (13) for the initial
, and go to
Step 2. A flow chart for CSVP is shown in Figure 7 .
Simulation of CSVP
All system parameters, the initial point, and the design variables except D and K 2 are as in the simulation in which the HIV patient does not reach LTNP status if CSCP is used. The initial values of D and K 2 are set as −0.6 and 1.5451, respectively. Also, both δD and δK 2 are defined as 0.1. To solve the minimization problem numerically, we use the Optimization Toolbox of Matlab.
Discussion
For the first seven days, all of the trajectories in Figure 8 are the same as those of the simulation shown in Figure 5 . Thereafter, once every period, the control method adjusts the parameters D and K 2 used by the reduced-order model (12) , (13) to emulate the behavior of the full-order model 36 IEEE CONTROL SYSTEMS MAGAZINE » APRIL 2008 FIGURE 6 A conceptual figure depicting the state trajectories of the real system and of the reduced-order model (12) , (13) . The points
, and (x F , y F ) are indicated. The thin dotted line indicates the CD4 T-cell count of the real system, while the thick dotted line indicates the viral load of the real system. Note that these levels of the CD4 T-cell count and viral load are measured only at the beginning of each period. The thin solid line indicates the x state of the reduced-order model (12) , (13) , while the thick solid line indicates the y state of the reducedorder model (12) , (13) . The difference between y F and y M (n N T) is considered to be the error between the reduced-order model (12) , (13) and the patient. Model (1)- (5) y(t) in Model (1)- (5) w(t ) in Model (1)- (5) y(t) in Model (12),(13)
Model (12), (13) (1)-(5). Although T is the same as in the simulation shown in Figure 5 , the patient state is induced to LTNP status in this case. Moreover, the state in Figure 8 converges faster than the state in Figure 4 .
CONCLUSIONS
The last two sections show how the suggested control strategies can drive the HIV patient's state to LTNP status. In this section, we comment on current problems related to HIV measurements and on the assumptions that are made in the simulations. We also discuss ideas for improving the given results.
Problems in HIV Measurements
Although a flow cytometer is a highly precise instrument, variability in the CD4 T-cell count can be a significant problem [24] . For example, CD4 Tcell counts normally undergo diurnal variation with fluctuation by as much as 150-300 copies/ mm 3 , while refrigeration of blood samples elevates the CD4 T-cell count. In addition, the CD4 T-cell count increases as samples wait for processing. These variations make it difficult to assess the real change in the CD4 T-cell population. Meanwhile, since each viral load test has particular characteristics, results from different tests may not be comparable [20] . In particular, a pair of tests carried out on the same sample of blood may vary significantly. Therefore, in clinical treatment the viral load trend is more important than the individual viral load measurement.
Assumptions on the Simulations
In the simulations, it is assumed that the full-order model (1)-(5) accurately describes the dynamics of the HIV patient. By this consideration, we show that the twodimensional system (12) , (13) An infected CD4 T-cell cannot fulfill its function in the immune system and becomes a virus factory, making multiple HIV copies. No medication is applied to the real system. u(n N T + n T + t) = 0, (0 ≤ t ≤ 1).
Yes
No y I (n N T+n T ) < K 2
Full HAART is applied to the real system. u(n N T+n T +t ) = u D (t), (0 ≤ t ≤ 1).
Integrate model (12), (13) for one day with (x I (n N T+n T ), y I (n N T+n T )) and u(n N T+ n T +t). From the solution, set x F = x(n N T+n T +1) and y F = y(n N T+n T +1). mean that the new control method is guaranteed to work for the clinical case. It is necessary to consider more detailed models of the real system and to work with clinicians. For example, the model in [29] is a ten-dimensional model including a continuously mutating viral population, although the model does not contain dynamics relating to the human immune system.
Although viral load test results are obtained in practice within ten days to two weeks [20] , this measurement delay is not considered in the simulations of this article. Hence, some modifications of the simulations and a more involved control scheme are required.
In addition, we assume that u D (t) is a square wave of amplitude one with one-day time period and 60% width. However, the dynamics of drug effect in the human body cannot be assumed to be a square wave. Further modeling of the drug delivery dynamics must be included in the full-order model (1)-(5).
FUTURE DIRECTIONS
As shown in Figure 8 , the behavior of the reduced-order model (12) , (13) approaches that of the full-order model (1)- (5) at each period with a steady series of square-wave inputs u(t). On the contrary, from the 100th day to the 350th day, where the input u(t) switches twice in each period T, the full-and reduced-order models do not show similar behavior. To increase the similarity between the behavior of the full-order model (1)- (5) and that of the reduced-order model (12) , (13), we can use the reducedorder model (12) , (13) when u(t) = 0 and an alternative model when u(t) = 1. Currently, the reduced-order model (12) , (13) is used for both u(t) = 0 and u(t) = 1, but this model is designed to emulate the full-order model (1)-(5) only when u(t) = 0. In addition, the control law used in CSCP and CSVP depends on the value of y in (12), (13) . This control law is simple and useful, as seen in the simulations. However, alternative control laws must be investigated, because the present law does not consider the cost of drugs, side effects of HAART, the duration of the anti-HIV therapy, and noise in the HIV measurements.
FIGURE 8
Simulation result of the control strategy with varying parameters D and K 2 when T = 7. These plots show the control input u(t) and state histories for the full-order model (1)-(5) and the reduced-order model (12), (13) . All of the system parameters, the initial point, and the design variables except D and K 2 are the same as those in the simulation in Figure 5 . Once every period T , the control method adjusts the parameters D and K 2 . The patient state is induced to LTNP status. Compared to the simulation in Figure 4 , the state converges faster to long-term nonprogressor status. x(t) in Model (1)- (5) x(t) in Model (12) , (13) y(t) in Model (1)- (5) y(t) in Model (12) , (13) w(t) in Model (1)- (5) LTNP is the status of a patient who has HIV but also a sufficient number of CD4 T-cells to fight off HIV and other infections.
